Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.
vyndaqel
-
Posted: May 03, 2019Categories: ApprovalsRead more »
-
Posted: December 17, 2018Categories: UpdatesRead more »
Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.
